Small-cell lung cancer (SCLC) comprises up to 20% of lung cancers, and continues to have a long-term survival rate in limited disease of only approximately 15%. Advanced stage disease is often fatal in less than 1 year. Over the last 30 years, the treatment for extensive stage SCLC has...
At the World Conference on Lung Cancer 2024 in San Diego, California, Daichi Fujimoto, MD, PhD, from the Hyogo Medical University in Japan shared treatment considerations for individuals diagnosed with small cell lung cancer (SCLC) with pre-existing interstitial lung disea...
of the mechanism of action of cytotoxic drugs) and radiation[3]. FDA-approved treatments for small cell lung cancer include doxorubicin, etoposide, mechlorethamine, methotrexate, topotecan, and everolimus − an mTOR protein kinase inhibitor (www.cancer.gov/about-cancer/treatment/drugs/lung)....
extensive-stage small-cell lung cancer; second-line treatments; biology and targeted therapies; new agents1. Introduction SCLC is a highly aggressive form of lung cancer, accounting for approximately 15% of all lung cancer cases with an annual incidence of over 200,000 cases worldwide [1]. In...
Combined small-cell carcinoma Both include many types of cells that grow and spread in different ways. They’re named according to what the cells look like under a microscope. Small-cell lung cancer differs from non-small-cell lung cancer in some key ways. Small-cell lung cancer: ...
The protein's essential role in tumor formation makes it an enticing target for researchers seeking to development new treatments for small-cell lung cancer (SCLC), an exceptionally dangerous form of cancer. Overall five-year survival for patients diagnosed with SCLC is only about 7%. ...
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. Despite high rates of response to first-line chemotherapy and radiotherapy, patients with extensive-stage disease eventually relapse, and very few patients survive more tha
Although newer treatments are being incorporated in the relapse setting, marked therapeutic resistance is typically observed in patients with relapsed small-cell lung cancer (SCLC), underscoring the need of developing more effective therapies in this setting. Notably, recent progress in the understanding...
Combination chemotherapy is the cornerstone of treatment of small cell lung cancer, leading to a meaningful survival benefit for these patients. However, there have been no major advances in therapy in the last decade. Therefore, more effective new treatments are necessary to improve the outcome of...
Small cell lung cancer (SCLC) is one of the two major types of lung cancer. It is named because the cells appear small and round under the microscope. Facts You Should Know About Small-Cell Lung Cancer When cells of the lung start to undergo a degenerative transformation in appearance and...